Protagonist Therapeutics has transformed into a royalty-driven company with two FDA-approved drugs and strong cash reserves. The company secured lucrative royalties and milestones from partners Takeda and J&J, reducing its operational risks while maintaining significant profit potential. Forward earnings estimates are nearly four times higher than past levels, supported by high-margin royalty income that could reach $605 million annually against $220 million in expenses. Key upcoming events include Q3 royalty recognition, execution of the $300 million buyback, and updates on its oral peptide drug pipeline.
Protagonist Therapeutics' recent transformation into a royalty compounder provides context for readers following biotech developments. For readers following the health sector, here is Pluang's market snapshot as of Oct 25, 2026 11:01 WIB: Among 150 health-sector US stocks tradable on Pluang, 44 rose and 105 fell today. Notable movers include AMWL at USD 13.57 with a -4.37% change and a typical hold time of 62 days, BNGO at USD 1.13 down 4.24% with 51 days hold, and ENVB at USD 1.40 down 4.11% with a notably shorter hold time of 15 days.
In Week 92 of President Trump's second term, the administration introduced a 1% commission program rewarding Americans for reporting government fraud. They have located many missing unaccompanied alien children from previous years and reported signif...
A snapshot from October 24 shows Solana (SOL) staking offers an implied annualized reward rate of about 5% after accounting for a typical 5% validator fee. Approximately 68.7% of the total SOL supply is staked, with a 3.59% inflation rate driving the...
Kaspa (KAS) is set to reduce its block subsidy by approximately 5.6% on November 4, 2026, lowering the base reward from about 2.06 KAS to 1.94 KAS per block. This change is part of a scheduled monthly reduction tied to the network's difficulty score,...
Solana's staking currently offers an annual yield of approximately 4.96% after a median validator commission of 5%, based on the network's issuance rate of 3.59% and 68.7% of all SOL tokens staked. Validators earn rewards proportional to the stake de...
A survey by the National Cryptocurrency Association found that half of crypto buyers in the past year lost money from hacks, fraud, or abandoned projects. Ripple's Chief Legal Officer Stuart Alderoty emphasized the need for clear, plain-language disc...
